UCB reported FY 2025 revenue of EUR 7.74 billion, up 26%, and net sales of EUR 7.39 billion, up 32%. Adjusted EBITDA rose 79% to EUR 2.64 billion (34% of revenue), and profit of the Group was EUR 1.56 billion, up 46%. Core EPS increased to EUR 9.99, and the board proposed a dividend of EUR 1.45 per share, up 4%. UCB said combined net sales of its five growth drivers more than doubled to over EUR 3.3 billion, driven by BIMZELX, EVENITY, FINTEPLA, RYSTIGGO and ZILBRYSQ. It highlighted FDA approval in November 2025 of KYGEVVI for thymidine kinase 2 deficiency, and a positive CHMP opinion in January 2026. The company also noted FDA Fast Track designation in February 2026 for bepranemab in Alzheimer’s disease and said first headline results from its BE BOLD Phase 4 psoriatic arthritis study are expected in H1 2026. For 2026, UCB guided for revenue growth in a high single-digit to low double-digit percentage range at constant exchange rates and adjusted EBITDA growth in a high single-digit to high teens percentage range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.